I-Sec upgrades GlaxoSmithKline Pharma to Add, lowers target price to Rs 2,250 Jobbery Stock Market update

ICICI Securities has raised its rating on GlaxoSmithKline Pharmaceuticals to Add from Hold with a new target price of Rs 2250. GSK Pharma’s earnings are expected to see a CAGR of 15.3% over FY24-27. The company has an asset-light and cash-rich balance sheet, which could improve its return on equity and return on capital employed.